Single Site, Phase 2B, Randomized, Double-Blind, and Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 Versus Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)

Trial Profile

Single Site, Phase 2B, Randomized, Double-Blind, and Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 Versus Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ALLOD 2 (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura; Nausea
  • Focus Therapeutic Use
  • Acronyms ANODYNE-2
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 29 Oct 2017 Planned number of patients changed from 90 to 60.
    • 11 Jul 2017 Planned End Date changed from 27 Oct 2018 to 1 Oct 2018.
    • 11 Jul 2017 Planned primary completion date changed from 27 Jun 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top